Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, BioAge Labs Presents Preclinical Data Showing APJ Agonism Enhances Glycemic Control And Cardioprotection In Diabetic Obesity And HFpEF

Author: Benzinga Newsdesk | June 23, 2025 02:58am

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
Data support development of next-generation APJ agonists for obesity and key comorbidities

Posted In: BIOA